All In Biotech

Drug Trial Radar · NCT02947048

Safety of L1-79 in Adolescent and Adult Males With Autism

A Randomized, Placebo-controlled Phase 2 Study With Open-Label and Double-Blind Portions to Evaluate the Safety of L1-79 in Adolescent and Young Adult Males With Autism

Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

42

Actual

Start

Oct 2016

Primary completion

Dec 2017

Study completion Feb 1, 2018

Sponsor

Lead sponsor
Yamo Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Oct 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a five-arm designed to assess the safety of L1-79 that incorporates 15 prospectively randomized, placebo controlled patients and 5 open label patients at either 100 tid (three times daily) or 200 tid dosing for 28 days. The open label patients will be assessed for the purpose of understanding PK/PD and to determine if there are any EKG changes associated with the administration of L1-79. Additional safety information will be provided by the 30 patients randomized 2:1 active:placebo.

Conditions

  • Autism

Interventions

  • L1-79Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eric Bartky MD, Bartky Health Care Center

    Livingston, New Jersey

  • F. Peter Halas MD, Sea Girt Pediatrics

    Sea Girt, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.